CDNA vs GH
CDNA: CareDx is a precision medicine leader providing diagnostic testing, digital health tools, and patient support services to improve outcomes for transplant and oncology patients. GH: Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum.
Side-by-side fundamentals
| Metric | CDNA | GH | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $43.71 | $161.99 | |
| Market cap as of 2026-08-03 | $2.3B | $21.7B | |
| PEG as of 2026-08-03 | 0.18 | -9.46 | GH lower |
| Net margin as of 2026-08-03 | -2.0% | -40.1% | CDNA higher |
| Gross margin as of 2026-08-03 | +68.9% | +64.9% | CDNA higher |
| Operating margin as of 2026-08-03 | -3.9% | -42.7% | CDNA higher |
| ROE as of 2026-08-03 | -2.6% | -246.6% | CDNA higher |
| ROA as of 2026-08-03 | -1.9% | -26.5% | CDNA higher |
| Debt / equity as of 2026-08-03 | 0.00 | 16.78 | CDNA lower |
| Revenue growth (YoY) as of 2026-08-03 | +19.2% | +39.6% | GH higher |
| Revenue CAGR (3y) SEC XBRL | +5.7% | +29.8% | GH higher |
| Beta as of 2026-08-03 | 1.31 | 1.21 | |
| 1-year return as of 2026-07-31 close | +255.8% | +295.3% | GH higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.